Rebecca Baab Riggins

This study examines how anti-HER2 therapy affects HER2 localization and ER genomic binding in ER+/HER2+ breast cancer, finding ER redistribution correlates with treatment resistance.

The paper develops a probability distribution for rare subclones in cancer and applies it to simulate dynamic precision medicine to improve treatment outcomes despite sequencing limitations.

This study examines how the size of glioblastoma spheroids affects their invasion and response to temozolomide therapy.

This study uses a 3D hydrogel model to investigate TMZ resistance in GBM by examining drug response and migration in heterogeneous cell populations.

This study enhances a personalized cancer treatment strategy by incorporating both irreversible and reversible drug resistance mechanisms, showing improved patient outcomes compared to current approaches.

This study shows FAM210B regulates iron homeostasis and sex-specific responses in stress erythropoiesis, with defects in spleen size and blood cell counts in knockout mice.

The paper examines glutamate-handling proteins in ILC and finds associations with tumor size, ER expression, and comorbidities, suggesting therapeutic targets.

This paper develops a 3D hydrogel model to study how acquired temozolomide resistance affects glioblastoma cell behavior, showing changes in drug sensitivity, invasion, and cytokine production.

CDGnet recommends targeted cancer therapies using a network approach that integrates biological pathway information and patient-specific molecular data.